Back to top

messenger-rna: Archive

Sundeep Ganoria

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.

MRKNegative Net Change MRNANegative Net Change IBRXPositive Net Change